Cardiovascular outcomes and safety of semaglutide in non-overweight populations with type 2 diabetes: a comparison with dipeptidyl peptidase 4 inhibitors.

Kishimori T, Kato T, Wada A, Tani A, Yamaji R, Koike J, Iwasaki Y, Matsumoto T, Yagi T, Okada M

European heart journal. Quality of care & clinical outcomes1 Dec 2025Cited by 3 (Europe PMC)

PMID40676725DOI10.1093/ehjqcco/qcaf065PepBankPUB-40676725

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanObservational studyEfficacy outcome
In adults with type 2 diabetes and BMI below 25 kg/m2, semaglutide was associated with a lower 3-year risk of all-cause mortality than DPP-4 inhibitors.
In plain wordsIn adults with type 2 diabetes and a lower body mass index, semaglutide was linked to fewer deaths than DPP-4 inhibitors.
Peptide
Semaglutide
Outcome
Decrease3-year all-cause mortality
Study
n = 8,388
Comparator
DPP-4 inhibitors
Analysis
Primary
Outcome group
Mortality · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
The semaglutide group had a significantly lower risk of all-cause mortality compared to the DPP-4 inhibitor group [6.1% vs. 10.7%, P < 0.001; hazard ratio (HR) 0.54, 95% confidence interval (CI) 0.45-0.65].
2 context sentences(design, population, supporting numbers)
Summary · context
We retrospectively compared all-cause mortality, cardiovascular outcomes, and adverse events in patients with T2D with a body mass index (BMI) < 25 kg/m² who received semaglutide or dipeptidyl peptidase 4 (DPP-4) inhibitors.
Summary · context
After propensity score matching, 4194 patients were included in each group.
Report a problemFND-4067672501
02HumanObservational studyEfficacy outcome
In adults with type 2 diabetes and BMI below 25 kg/m2, semaglutide was not associated with the incidence of acute myocardial infarction compared with DPP-4 inhibitors.
In plain wordsIn adults with type 2 diabetes and a lower body mass index, semaglutide was not linked to heart attack rates different from DPP-4 inhibitors.
Peptide
Semaglutide
Outcome
No significant changeAcute myocardial infarction
Study
n = 8,388
Comparator
DPP-4 inhibitors
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Semaglutide was not associated with the incidence of AMI (6.1% vs. 7.1%, P = 0.173; HR 0.87, 95% CI 0.72-1.06)
2 context sentences(design, population, supporting numbers)
Summary · context
We retrospectively compared all-cause mortality, cardiovascular outcomes, and adverse events in patients with T2D with a body mass index (BMI) < 25 kg/m² who received semaglutide or dipeptidyl peptidase 4 (DPP-4) inhibitors.
Summary · context
After propensity score matching, 4194 patients were included in each group.
Report a problemFND-4067672502
03HumanObservational studyEfficacy outcome
In adults with type 2 diabetes and BMI below 25 kg/m2, semaglutide was not associated with the incidence of stroke compared with DPP-4 inhibitors.
In plain wordsIn adults with type 2 diabetes and a lower body mass index, semaglutide was not linked to stroke rates different from DPP-4 inhibitors.
Peptide
Semaglutide
Outcome
No significant changeStroke
Study
n = 8,388
Comparator
DPP-4 inhibitors
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
or stroke (8.4% vs. 7.7%, P = 0.220; HR 1.11, 95% CI 0.94-1.32).
2 context sentences(design, population, supporting numbers)
Summary · context
We retrospectively compared all-cause mortality, cardiovascular outcomes, and adverse events in patients with T2D with a body mass index (BMI) < 25 kg/m² who received semaglutide or dipeptidyl peptidase 4 (DPP-4) inhibitors.
Summary · context
After propensity score matching, 4194 patients were included in each group.
Report a problemFND-4067672503
04HumanObservational studySafety outcome
In adults with type 2 diabetes and BMI below 25 kg/m2, nausea and vomiting did not differ significantly between semaglutide and DPP-4 inhibitors.
In plain wordsIn adults with type 2 diabetes and a lower body mass index, nausea and vomiting were not significantly different between semaglutide and DPP-4 inhibitors.
Peptide
Semaglutide
Outcome
No significant changeNausea and vomiting
Study
n = 8,388
Comparator
DPP-4 inhibitors
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Adverse events, including nausea and vomiting, diarrhoea, and hypoglycaemia, were not significantly different between the groups.
2 context sentences(design, population, supporting numbers)
Summary · context
We retrospectively compared all-cause mortality, cardiovascular outcomes, and adverse events in patients with T2D with a body mass index (BMI) < 25 kg/m² who received semaglutide or dipeptidyl peptidase 4 (DPP-4) inhibitors.
Summary · context
After propensity score matching, 4194 patients were included in each group.
Report a problemFND-4067672504
05HumanObservational studySafety outcome
In adults with type 2 diabetes and BMI below 25 kg/m2, diarrhoea did not differ significantly between semaglutide and DPP-4 inhibitors.
In plain wordsIn adults with type 2 diabetes and a lower body mass index, diarrhoea was not significantly different between semaglutide and DPP-4 inhibitors.
Peptide
Semaglutide
Outcome
No significant changeDiarrhoea
Study
n = 8,388
Comparator
DPP-4 inhibitors
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Adverse events, including nausea and vomiting, diarrhoea, and hypoglycaemia, were not significantly different between the groups.
2 context sentences(design, population, supporting numbers)
Summary · context
We retrospectively compared all-cause mortality, cardiovascular outcomes, and adverse events in patients with T2D with a body mass index (BMI) < 25 kg/m² who received semaglutide or dipeptidyl peptidase 4 (DPP-4) inhibitors.
Summary · context
After propensity score matching, 4194 patients were included in each group.
Report a problemFND-4067672505
06HumanObservational studySafety outcome
In adults with type 2 diabetes and BMI below 25 kg/m2, hypoglycaemia did not differ significantly between semaglutide and DPP-4 inhibitors.
In plain wordsIn adults with type 2 diabetes and a lower body mass index, hypoglycaemia was not significantly different between semaglutide and DPP-4 inhibitors.
Peptide
Semaglutide
Outcome
No significant changeHypoglycaemia
Study
n = 8,388
Comparator
DPP-4 inhibitors
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Adverse events, including nausea and vomiting, diarrhoea, and hypoglycaemia, were not significantly different between the groups.
2 context sentences(design, population, supporting numbers)
Summary · context
We retrospectively compared all-cause mortality, cardiovascular outcomes, and adverse events in patients with T2D with a body mass index (BMI) < 25 kg/m² who received semaglutide or dipeptidyl peptidase 4 (DPP-4) inhibitors.
Summary · context
After propensity score matching, 4194 patients were included in each group.
Report a problemFND-4067672506

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Cardiovascular outcomes and safety of semaglutide in non-overweight populations with type 2 diabetes: a comparison with dipeptidyl peptidase 4 inhibitors.

Summary

Results from this study6

Version history

Subjects

Publication types

MeSH terms

Keywords